We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Download Mobile App




Superior Single-Cell Library Preparation Technology Now Available for Additional Platforms

By LabMedica International staff writers
Posted on 17 Feb 2014
Innovative single-cell DNA library preparation kits can now be used with Illumina sequencing platforms.

Rubicon Genomics (Ann Arbor, MI, USA) now offers its PicoPLEX DNA-seq kits for use with Illumina next-generation sequencing (NGS) platforms. More...
The kits are among Rubicon’s sample-specific library preparation products used in clinical and research testing on NGS, microarray, and quantitative polymerase chain reaction (qPCR) platforms. PicoPLEX’s excellent robustness and reproducibility offer excellent single-cell DNA amplification for microarray and PCR-based preimplantation genetic screening and diagnosis. PicoPLEX DNA-seq now enables clinicians and researchers to access PicoPLEX technology for analyses conducted on Illumina NGS systems.

PicoPLEX DNA-seq kits amplify DNA to yield a highly reproducible NGS-ready library from a single cell with input concentrations of six picograms or less. PicoPLEX DNA-seq employs the same technology currently used by in vitro fertilization (IVF) clinics to detect chromosomal aneuploidies, copy number variations, and single-gene disorders in reproductive cells. It is also used for the genetic characterization of other single-cell samples such as circulating tumor cells. The easy-to-use, three-step process is performed in a single tube or well in less than 3 hours, thereby reducing error and contamination, speeding time to results, and reducing costs.

James Koziarz, PhD, CEO of Rubicon Genomics, commented, “PicoPLEX DNA-seq emphasizes our commitment to increasing the robustness and reproducibility of DNA analyses while also delivering greater speed, efficiency and cost savings. This launch represents another milestone in our ongoing strategy to make Rubicon Genomics’ proprietary library preparation technology available to users of all sequencing platforms.”

Dr. Brian Mariani, chief scientist and scientific director of the Genetics and IVF Institute, helped test the PicoPLEX DNA-seq kits. He commented, “Remarkably, the sequencing data from the PicoPLEX DNA-seq libraries of embryo DNA clearly identified a male balanced translocation that had not been detected by previous microarray and FISH [fluorescence in-situ hybridization] analyses. This is a significant example of how PicoPLEX sequencing data can expose important structural rearrangements missed by other approaches.”

At the 15th annual Advances in Genome Biology and Technology meeting (AGBT 2014; February 12–15, 2014, Marco Island, FL, USA), Rubicon CSO Dr. John Langmore presented studies highlighting PicoPLEX DNA-seq and discussed “Preimplantation genetic screening and diagnostics (PGS/PGD) at low NGS coverage for aneuploidy, CNV, and single-gene disorder detection for in vitro fertilization.”

Related Links:

Rubicon Genomics
PicoPLEX DNA-seq
Advances in Genome Biology and Technology Meeting



Platinum Member
Xylazine Immunoassay Test
Xylazine ELISA
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
NEW PRODUCT : SILICONE WASHING MACHINE TRAY COVER WITH VICOLAB SILICONE NET VICOLAB®
REGISTRED 682.9
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.